A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (TTM) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism.

A method of treating a cancer disease or pre-disease condition in a mammal comprising administering a first pharmaceutical composition including a therapeutically effective amount of a first therapeutic, wherein the first therapeutic is tetrandrine, a tetrandrine derivative, or pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, or a combination thereof.

Compositions for stabilizing and delivering proteins and/or other bioactive agents are disclosed. The bioactive agents are embedded or encapsulated in a crystalline matrix. Typically the bioactive agents are in the form of micro- or nanoparticles. The crystalline matrix confers enhanced stability to the agents embedded therein relative to other microparticulate or nanoparticulate bioactive agents. The carriers are especially useful for stabilizing bioactive macromolecules, such as proteins.

Systems and methods for purification and concentration of autologous alpha-2 macroglobulin (A2M) from whole blood and or recombinant A2M are provided. Also provided are methods of treating wounds with A2M. Methods for utilizing A2M in combination with other treatments (e.g., platelets and other growth factors) are provided in addition to combinations with exogenous drugs or carriers. Also provided is a method of producing recombinant A2M wild type or variants thereof where the bait region was modified to enhance the inhibition characteristics of A2M and/or to prolong the half-life of the protein for treating wounds.

Systems and methods for purification and concentration of autologous alpha-2 macroglobulin (A2M) from whole blood and or recombinant A2M are provided. Also provided are methods of treating wounds with A2M. Methods for utilizing A2M in combination with other treatments (e.g., platelets and other growth factors) are provided in addition to combinations with exogenous drugs or carriers. Also provided is a method of producing recombinant A2M wild type or variants thereof where the bait region was modified to enhance the inhibition characteristics of A2M and/or to prolong the half-life of the protein for treating wounds.

A composition comprising TGFβ, an inflammatory agent and a tryptophan indoleamine-2,3 dioxygenase (IDO) metabolite, in particular, TGFβ, IFNγ and kynurenine, is provided, as well as regulatory mesenchymal stem cell lines or myeloid-derived suppressor cell lines obtained by contacting mesenchymal stem cell lines or myeloid-derived suppressor cell lines, respectively, with the composition. Methods for inhibiting proliferation of T cells, reducing Th17 and Tc17 differentiation of activated T cells and inflammation or for treating inter alia graft-versus-host disease (GVHD), comprising administering the cell lines, are further provided.

A composition comprising TGFβ, an inflammatory agent and a tryptophan indoleamine-2,3 dioxygenase (IDO) metabolite, in particular, TGFβ, IFNγ and kynurenine, is provided, as well as regulatory mesenchymal stem cell lines or myeloid-derived suppressor cell lines obtained by contacting mesenchymal stem cell lines or myeloid-derived suppressor cell lines, respectively, with the composition. Methods for inhibiting proliferation of T cells, reducing Th17 and Tc17 differentiation of activated T cells and inflammation or for treating inter alia graft-versus-host disease (GVHD), comprising administering the cell lines, are further provided.

The present invention relates, inter alia, to compositions and methods, including chimeric proteins having a first domain comprising an extracellular domain of a first transmembrane protein, a first secreted protein, or a first membrane-anchored extracellular protein and a second domain comprising an extracellular domain of a second transmembrane protein, a second secreted protein, or a second membrane-anchored extracellular protein, in which either or both of the first domain and the second domain decreases self-directed immune system activity when bound to its ligand/receptor. Accordingly, the present invention find use in the treatment of autoimmune diseases.

Disclosed herein are methods, compositions, and kits for treating a B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g. ibrutinib) and a PIM inhibitor. Also disclosed herein are methods, compositions, and kits for treating a BTK-resistant B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g. ibrutinib) and a PIM inhibitor.

Disclosed herein are methods, compositions, and kits for treating a B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g. ibrutinib) and a PIM inhibitor. Also disclosed herein are methods, compositions, and kits for treating a BTK-resistant B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g. ibrutinib) and a PIM inhibitor.